Colorectal Cancer

Thierry Andre, MD, discusses subgroup and safety analyses of the phase 3 CheckMate 8HW trial of frontline nivolumab plus ipilimumab in MSI-H/dMMR mCRC.

In the NO-CUT trial, 97% of patients with pMMR locally advanced rectal cancer sustained distant relapse-free survival with nonoperative management.

Ramucirumab plus trifluridine/tipiracil failed to improve overall survival vs TAS-102 alone in patients with heavily pretreated metastatic colorectal cancer.

Encorafenib, cetuximab, and FOLFIRI demonstrate promising antitumor activity in patients with BRAF V600E-mutant metastatic colorectal cancer.

Zanidatamab plus chemotherapy with or without bevacizumab showed efficacy and safety in previously untreated HER2-positive metastatic colorectal cancer.

Richard Kim, MD, discusses the safety of NT-17 and next steps for its evaluation in pretreated microsatellite stable CRC and PDAC.

This list features a snapshot of key August FDA oncology decisions, efforts to integrate health equity into guideline development, and more.

Arvind Dasari, MD, MS, discusses considerations and challenges associated with treating patients in the later-line colorectal cancer setting.

The NuTide:323 trial of NUC-3373 plus leucovorin, irinotecan, and bevacizumab in second-line colorectal cancer has been discontinued.

Arvind N. Dasari, MD, MS, discusses later-line treatment considerations for patients with unresectable metastatic colorectal cancer.

Arvind Dasari, MD, MS, discusses fruquintinib as later-line treatment for patients with advanced metastatic colorectal cancer.

Oxaliplatin plus fluoropyrimidine and bevacizumab confers little therapeutic benefit to older patients with metastatic colorectal cancer.

John H. Strickler, MD, discusses the significance of fruquintinib for patients with metastatic colorectal cancer who have exhausted standard therapies.

Michael Cecchini, MD, discusses findings from the ARC-9 trial investigating an etrumadenant-based combination in patients with previously treated mCRC.

Drs Park and Kasi delve into the shift toward neoadjuvant immunotherapy and the use of ctDNA as a prognostic tool in colorectal cancer.

Aparna Parikh, MD, discusses the rationale for adding ERAS-007 to the BEACON regimen in BRAF V600E–mutated metastatic colorectal cancer.

Rona Yaeger, MD, details the FDA approval of adagrasib plus cetuximab in KRAS G12C-mutated colorectal cancer and how the approval will advance the field.

Richard Kim, MD, discusses the current treatment paradigm for patients with resectable CRC, as well as unmet needs in this population.

Eric S. Christenson, MD, discusses the safety of copanlisib plus nivolumab in pretreated, PIK3Ca-mutated microsatellite stable, unresectable or metastatic colorectal cancer.

Rene Adam, MD, PhD, discusses future research aimed at reducing the risk of recurrence in patients with unresectable colorectal liver metastases

Chiara Cremolini, MD, PhD, discusses the implications of the TRANSMET trial in patients with unresectable colorectal liver metastases.

Tanios Bekaii-Saab, MD, FACP, discusses final results from the MOUNTAINEER trial in HER2+ metastatic colorectal cancer.

The Guardant Reveal test was accurate in predicting disease recurrence in stage II or higher colorectal cancer.

ABBV-400 displayed efficacy and tolerability in microsatellite stable/mismatch repair–proficient advanced colorectal cancer.

The European Medicines Agency has approved Avzivi, a biosimilar referencing bevacizumab.